Vlad Vitoc Buys 73,000 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc purchased 73,000 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of $1.37 per share, for a total transaction of $100,010.00. Following the completion of the acquisition, the chief executive officer directly owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. This represents a 7.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

MAIA Biotechnology Stock Up 4.5%

NYSEAMERICAN MAIA opened at $1.40 on Thursday. The firm has a market cap of $85.16 million, a PE ratio of -2.26 and a beta of 0.25. The company has a 50 day moving average price of $1.35 and a 200 day moving average price of $1.37. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $3.19.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new position in MAIA Biotechnology during the 2nd quarter valued at approximately $51,000. Cable Car Capital LP purchased a new position in shares of MAIA Biotechnology in the second quarter worth $741,000. BlackRock Inc. acquired a new stake in shares of MAIA Biotechnology during the second quarter worth $580,000. Centric Wealth Management purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at $1,107,000. Finally, PVG Asset Management Corp acquired a new position in shares of MAIA Biotechnology in the 1st quarter valued at $46,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research centers on telomeres, protective structures at the ends of chromosomes that are maintained in many cancer cells through telomerase activity.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine (6-thio-dG). The compound is designed to be activated in telomerase-positive cancer cells, promoting telomere dysfunction and DNA damage that may lead to cancer-cell death.